Contact Us

Duragesic Patch
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

   * Please describe your case:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Pain Relief Patch Studied In 120 Deaths

Jul 16, 2005 | Los Angeles Times

Federal regulators are investigating about 120 reported deaths that may be linked to overdoses from a pain relief patch that administers a potent narcotic through the skin, the Food and Drug Administration said Friday.

Johnson & Johnson's Duragesic patch can provide up to three days' relief from severe chronic pain, such as that experienced by bone cancer patients. But fentanyl, its active ingredient, is highly dangerous. An overdose of the morphine-like drug can put a patient into a coma and shut down breathing.

Fentanyl gained international notoriety in 2002, when Russian authorities trying to end a hostage crisis at a Moscow theater pumped in a gas reportedly containing the drug, intending to put the hostages and their Chechen captors to sleep. Of the 750 hostages, about 120 died, nearly all from breathing the gas.

FDA officials said they are investigating whether the deaths among U.S. patients could be the result of unintentional fentanyl overdoses. Such overdoses could come about if patients and doctors do not faithfully follow a series of precautions contained in the prescribing literature, or label, for the drug.

Other possible explanations include rare problems or defects with the patches themselves that would cause too much of the drug to be released into the body too quickly.

Doctors and patients should be aware of the signs of fentanyl overdose, which include trouble breathing or shallow breathing, tiredness, extreme sleepiness, inability to think, talk or walk normally and feeling faint, dizzy or confused, the FDA said. Patients experiencing these symptoms should get medical attention right away, the FDA said.

FDA officials said the agency announced the investigation in keeping with its new commitment to give the public warning of possible problems with prescription drugs. The FDA has been strongly criticized for taking too long to respond to evidence of heart attack risks with Vioxx and other arthritis drugs, and to evidence of suicide risks for teenagers taking anti-depressants.

The fentanyl investigation is in its early stages, FDA officials said, and the agency has reached no decision on whether the patches should be recalled, or their use limited. But the FDA did issue a new public health advisory Friday underscoring the need for patients to follow precautions for using the drug scrupulously.

Because of its risks, Duragesic and its generic equivalent already carry a so-called "black box" warning, the FDA's most emphatic.

On Friday, the agency underscored those warnings.

Doctors should prescribe the lowest effective dose of the medication, said the agency. And fentanyl patches should not be used to treat short-term pain, or pain after an operation. Patients should not attempt to use any patches that are damaged or broken. And they should not drink alcoholic beverages or bask in the sun while taking the drug because alcohol and a rise in body temperature can accentuate the effects.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo